Stoke Therapeutics, a pioneering biotechnology company listed on Nasdaq as STOK, has successfully secured $165 million in its latest funding round, marking a significant milestone in its mission to address the underlying causes of severe diseases. The company is revolutionizing how we approach therapies by focusing not on replacing, repairing, or editing genes, but on enhancing the output of healthy genes. Utilizing its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform, Stoke is uniquely positioned to boost protein production from intact genes, restoring functional protein levels crucial for patients suffering from haploinsufficiencies—conditions resulting from the loss of about half the normal protein function. With nearly 6,500 genes identified to have a TANGO signature, the potential reach of this strategy spans a broad spectrum of severe disorders. The recent infusion of capital will accelerate the development and clinical testing of their promising pipeline, including STK-001, their lead candidate, which has shown positive Phase 1/2 results in treating Dravet syndrome—a severe genetic epilepsy associated with debilitating non-seizure comorbidities. Additionally, funding will support the advancement of STK-002, a candidate therapy for autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder, with clinical trials slated to commence in 2024. Beyond these programs, the investment will further bolster collaborative efforts with partners like Acadia Pharmaceuticals on treatments for neurodevelopmental disorders such as Syngap1 and Rett syndrome. Headquartered in Bedford, Massachusetts, with additional offices in Cambridge, Stoke Therapeutics is committed to transforming the treatment landscape for severe diseases, and this funding will catalyze its journey towards making a tangible difference in patients' lives.
Stoke Therapeutics Secures $165M to Ignite a New Era in Neuro and Ocular Disease Treatment
Recently funded · $165.0MBiotechnology
Get the full Stoke Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
